Defining the role of neoadjuvant systemic therapy in high-risk retroperitoneal sarcoma: A multi-institutional study from the Transatlantic Australasian Retroperitoneal Sarcoma Working Group.
William W TsengFrancesco BarrettaLorenzo ContiGiovanni GrignaniFrancesco TolomeoMarkus AlbertsmeierMartin K AngelePiotr RutkowskiJacek SkoczylasAntonino De PaoliFederico NavarriaChandrajit P RautMark FairweatherJeffrey M FarmaCarolyn NessimNeha GoelValerie P GrignolSamuel J FordKenneth CardonaTy SubhawongHannah L TattersallRachel M LeeJames S HuMargaret von MehrenRoberta SanfilippoAlessandro GronchiPublished in: Cancer (2020)
In patients with high-risk RPS, the response to neoadjuvant systemic therapy is fair overall. Disease progression on therapy may be used to predict survival after surgery. Subtype-specific regimens should be further validated.